Oxidative Damage May Lead to Neurocognitive Decline

Share this content:

the Cancer Therapy Advisor take:

Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood acute lymphoblastic leukemia (ALL), according to a recent study published online ahead of print in the Journal of Clinical Oncology.

Researchers led by Peter Cole, MD, of the Albert Einstein College of Medicine examined genomic DNA that was isolated from bone marrow in 350 pediatric leukemia survivors.

“This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline,” they stated.

These polymorphisms were selected based on prior literature. Multivariable logistic regression models were used to estimate the association between genotype and neurocognitive outcomes.

They found that inferior cognitive or behavioral outcomes were associated with polymorphisms in three genes (NOS3, SLCO2A1, and COMT) that were related to oxidative stress or neuroinflammation. 

Pediatric patients treated with ifosfamide-doxorubicin chemotherapy and radiotherapy experienced sat
Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood ALL.
Survivors of childhood ALL exhibit increased rates of neurocognitive deficits. This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs